News
-
6 Dec, 2021
Tumorad® visar god säkerhet i prekliniska studier
-
2 Dec, 2021
Second dose group fully recruited in Spago Nanomedical’s phase 1 study with SpagoPix
-
2 Dec, 2021
Andra dosgruppen färdigrekyterad i Spago Nanomedicals fas 1-studie med SpagoPix
-
10 Nov, 2021
Spago Nanomedical delårsrapport januari-september 2021
-
10 Nov, 2021
Spago Nanomedical interim report January-September 2021
-
10 Nov, 2021
Spago Nanomedical selects Cmed as its CRO for the first clinical trial with Tumorad®
-
10 Nov, 2021
Spago Nanomedical anlitar Cmed som CRO för den första kliniska studien med Tumorad®
-
21 Oct, 2021
Nomination committee appointed for the 2022 Annual General Meeting in Spago Nanomedical
-
21 Oct, 2021
Valberedning utsedd inför Spago Nanomedicals årsstämma 2022
-
24 Aug, 2021
Spago Nanomedical halvårsrapport januari-juni 2021